– USA, CA – Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, announced the appointment of Justin Gover to its Board of Directors, effective immediately.
About Justin Gover
Justin Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding CEO of GW Pharmaceuticals plc, guiding the company for over two decades, from inception through its strategic $7 billion acquisition by Jazz Pharmaceuticals in 2021. During his tenure, GW grew into a fully integrated global biotech organization and successfully commercialized Epidiolex (cannabidiol), which is approved in the U.S. and Europe for the treatment of childhood-onset epilepsies.
Justin Gover serves on the boards of Compass Pathways plc (Nasdaq: CMPS) and Xenon Pharmaceuticals (Nasdaq: XENE) in addition to his work with nonprofit organizations, including the Rady Children’s Hospital Institute for Genomic Medicine and CURE Epilepsy. From 2018 to 2021, he served on the Board of Directors of the Biotechnology Innovation Organization (BIO).
Justin Gover holds an M.B.A. from the INSEAD business school in France and a BSc (Hons) from Bristol University.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC gene-targeted chimera small molecules. The company’s GeneTAC molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines.
For more: https://www.designtx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.